A single-group, open-label, phase 2 trial of NNZ‑2591 in children and adolescents with Phelan‑McDermid syndrome reports meaningful improvements across communication, cognition, behavior, GI symptoms, and sleep, with a favorable safety profile.

Background and Objectives.